The mutations in STK-012 result in reduced CD132 binding and therefore STK-012 is strongly biased towards CD25 expressing cells such as tumor antigen activated T cells and away from cells with low CD132 expression such as NK cells. The gene discussed is IL2RA; the disease is neoplasm.